Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372624 | 0.84 | SLC33A1 (0.45) | ACHEAGTR1 | |
| SCHEMBL1371171 | 0.78 | SLC33A1 (0.48) | PPARG | |
| SCHEMBL1373267 | 0.75 | SLC33A1 (0.47) | PPARG | |
| SCHEMBL1892431 | 0.75 | ACHE (0.46) | ACHEAGTR1PPARG | |
| SCHEMBL8671011 | 0.74 | ACHE (0.45) | ACHEAGTR1PPARG | |
| SCHEMBL12348665 | 0.74 | ACHE (0.45) | ACHEAGTR1PPARGAPLNR | |
| SCHEMBL1894561 | 0.74 | ACHE (0.45) | ACHEAGTR1PPARGAPLNR | |
| SCHEMBL1372069 | 0.74 | ACHE (0.45) | ACHEAGTR1PPARG | |
| SCHEMBL7313672 | 0.74 | PPARG (0.46) | ACHEAGTR1PPARGAGTR2APLNR | |
| SCHEMBL1892195 | 0.74 | ACHE (0.44) | ACHEAGTR1PPARGAGTR2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115136-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| US-8921379-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140046056-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
| US-8592431-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| EP-2384327-B1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-07-31 | — | — | EP | disclosed |
| US-8283353-B2 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20110294832-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-12-01 | — | — | US | disclosed |
| US-20110288087-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-11-24 | — | — | US | disclosed |
| US-20100197683-A1 | FUSED RING COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046056-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | ACHE 4010/4885AGTR1 4/4885PPARG 2/4885 |
| US-20110288087-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | ACHE 4010/4885AGTR1 4/4885PPARG 2/4885 |
| US-20110294832-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | ACHE 4010/4885AGTR1 4/4885PPARG 2/4885 |
| US-20100197683-A1 | FUSED RING COMPOUND AND USE THEREOF | PPARA, PPARG, AGTR2 | ACHE 4010/4885AGTR1 4/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.